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Central nervous system inflammation and neurodegeneration are the pathophysiological
hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current
diseasemodifying drugs, neurodegeneration is by far less accessible to treatment. Based
on suggested additional neuroprotective capacities of the orally available non-opioid and
centrally acting analgesic drug flupirtine maleate we hypothesized that treatment with
flupirtine maleate might be beneficial in MS patients. The flupirtine as oral treatment
in multiple sclerosis (FLORIMS) study was a multi-center, randomized and stratified,
placebo-controlled double-blind phase II trial to investigate safety and efficacy in terms of
clinical and radiographical activity of flupirtine maleate (300mg per day) given orally for 12
months, add-on to interferon beta 1b subcutaneously in patients with relapsing remitting
MS. Due to a substantial delay in recruitment, enrolment of patients was prematurely
terminated after randomization of only 30 of the originally planned 80 patients. Of
these, 24 regularly terminated study after 12 months of treatment. Data were analyzed
as originally planned. Treatment with flupirtine maleate was overall well tolerated. We
observed moderate and asymptomatic elevations of liver enzymes in several cases but
no overt hepatotoxicity. Neither the intention to treat nor the per protocol analysis revealed
any significant treatment effects of flupirtine maleate with respect to occurrence of MS
relapses, disability progression, or development of new lesions on cranial MRI. However,
substantial methodological limitations need to be considered when interpreting these
results. In conclusion, the results of the FLORIMS study neither add further evidence
to nor argue against the hypothesized neuroprotective or disease modifying effects of
flupirtine maleate in MS.
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INTRODUCTION
Neurodegeneration, i.e., damage to neuronal and axonal
structures is a histopathological hallmark of multiple sclerosis
(MS) (1), occurs already early in the course of disease (2), and
is considered responsible for the development of irreversible
neurological deficits (3, 4). Whether neurodegeneration in MS
occurs exclusively secondary to an underlying autoimmune
attack to central nervous system (CNS) structures or is in part
a primary feature is a matter of debate. Beyond dispute is the
perception that prevention of neurodegeneration is a highly
important albeit largely unmet need in the treatment of MS (5).
Flupirtine maleate (hereafter referred to as flupirtine) is
an orally available, non-opioid and centrally acting analgesic
drug and is licensed in many European countries for the
treatment of acute and chronic pain. Interestingly, it was never
licensed in the United States. For decades, it was considered
well tolerable without cancero- or teratogenic capacities and
without a potential for tolerance and dependency even in long
term use (6, 7). Nonetheless, potentially severe hepatotoxicity
has been reported (8) which resulted in the confinement of
indication in 2013. In 2018, the European Medical Agency
(EMA) recommended withdrawal from the market.
Its main mode of action is stabilization of the neuronal
membrane potential by selective opening of inwardly rectifying
neuronal potassium channels. Flupirtine can cross the blood
brain barrier (9, 10), and several lines of both in vitro and in
vivo evidences from animal models suggest that flupirtine has
neuroprotective properties (11–14). Furthermore, we have shown
that flupirtine protects neurons from cytokine mediated death in
a human living brain slice culture model (15). Also, a significantly
increased survival of retinal ganglion cells and an improved
visual function was observed in a rat model of autoimmune optic
neuritis when animals were treated with flupirtine in addition to
interferon beta (16). In a double blind placebo controlled trial
in patients with Creutzfeld Jakob disease flupirtine treatment
supported the preservation of cognitive functions (17).
Based on these promising data and long before the
hepatotoxicity issue became evident we hypothesized that
daily flupirtine intake prevents patients from MS-induced
neuroaxonal damage and addressed this hypothesis in an
investigator-initiated double blind randomized placebo-
controlled interventional trial using clinical and magnetic
resonance imaging (MRI) metrics as exploratory outcome
parameters.
METHODS
Study Design and Ethics Statement
The flupirtin as oral treatment in multiple sclerosis (FLORIMS)
study was designed as a multi-center, randomized and stratified,
placebo-controlled, double-blind, explorative phase II trial. The
aim was to investigate safety and efficacy in terms of clinical
and MRI activity of flupirtine (final dose 100–0–200mg per day)
given orally for 12 months, add-on to interferon beta 1b (IFN β-
1b) subcutaneously in patients with relapsing remitting (RR)MS.
Originally planned was the enrolment of 80 RRMS patients (40
per study arm) at four German study centers (Berlin, Göttingen,
Ulm, Cottbus, for details see Supplementary Material 1). Due to
unforeseen difficulties in the recruitment of eligible participants,
enrolment was prematurely terminated after inclusion of only 30
patients during a recruitment period of 60 months (December
2007–November 2012). The study was approved by the German
Federal Institute for Drugs and Medical Devices (BfArM,
4032838), as well as by the local ethics committees (ZS
EK 15510/06), and is registered at European Clinical Trials
Database (EudraCT 2006-005262-39) and ClinicalTrials.gov
(NCT00623415). It was conducted strictly adhering to the study
protocol and to applicable national laws (Arzneimittelgesetz,
14. Novelle, 2005), the Harmonized Tripartite Guideline for
Good Clinical Practice (ICH GCP) and the principles of the
Declaration of Helsinki in its applicable version. All participants
gave written informed consent at screening prior to any study-
related procedures.
The trial design is presented in Figure 1. After a short
screening period eligible patients were stratified according to
sex and T2 weighted (T2w) hyperintense lesion load in the
baseline MRI and were then randomized 1:1 to either verum
or placebo treatment add-on to continuing treatment with IFN
β-1b. In the verum group, flupirtine was started at a dose of
100mg once daily. After 2 weeks, the dose was increased to
100mg twice daily, and after another 2 weeks to 100–0–200mg.
Treatment was continued for 12 months. Clinical evaluations
including expanded disability status scale (EDSS) (18) and MS
functional composite (MSFC) (19) were performed every 3
months, standardized MRI was performed at screening and after
6 and 12 months. Pharmacovigilance laboratory testing was done
at least monthly in the first 6 months and thereafter every 3
months.
Designed as an explorative trial, no formal primary endpoint
was defined in advance. For the same reason, no statistical sample
size determination was accomplished.
All study participants had a minimum pretreatment of 6
months with IFN β1b. After a short screening period (1 week),
patients were stratified and randomized 1:1 to receive either
verum or placebo. The study drug dose was increased from
100mg once daily for 2 weeks over 100mg twice daily for
the following 2 weeks to the final dose of 100–0–200mg.
Patients were kept on this dose for the next 11 months. Main
investigations were performed at the time points displayed. Safety
visits including vital signs and blood tests were done at months
0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, and 12.
Study Population
The main inclusion criteria were: male and female patients with a
definite diagnosis of MS according to the 2005 revisedMcDonald
criteria (19) and a relapsing remitting disease course; age 18–
55 years; EDSS score of 0–4 (18); continuous treatment with
IFN β1b for at least 6 months. Important exclusion criteria
were: preexisting liver disease or treatment with hepatotoxic
drugs; any other CNS disease; pregnancy; inability to provide
informed consent; incompatibility with MRI procedures. A
comprehensive listing of in- and exclusion criteria is provided in
the Supplementary Material 2.
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FIGURE 1 | Design of the FLORIMS study. scr, screening; EDSS, expanded disability status scale; IFN, interferon; m, month; MRI, magnetic resonance imaging;
MSFC, multiple sclerosis functional composite; rand, randomization.
Outcome Measures
All evaluations and scorings were performed by trained
evaluators blinded to the patients’ treatment allocations. Relapses
were counted on the basis of generally accepted relapse
definitions: (re)occurrence of new or previous CNS dysfunction
in the absence of infections or hyperthermia, duration ≥24 h,
time-lag from onset of previous relapse ≥30 days. MS-related
disability was assessed by EDSS and MSFC (18, 19). EDSS
scoring was performed by trained and certified (Neurostatus)
physicians otherwise not involved in the management of study
participants. MSFC scoring was done by trained study personnel
according to standardized operating procedures. Standardized
MRI scanning in all participants was done at the study center
at Charité-Universitaetsmedizin Berlin using a 1.5 Tesla scanner
(Siemens Medical Systems, Erlangen, Germany) as previously
described (20). In short, an axial triple echo spin-echo sequence
(TR 5,780ms, TE1 13ms, TE2 81ms, TE3 121ms, 3mm slice
thickness, 44 contiguous axial slices) was used to obtain proton
density and T2w images. Additionally, we applied an axial fluid-
attenuated inversion recovery sequence (TIRM, TR 10,000ms,
TE 108ms, TI 2,500ms, 3mm slice thickness, 44 contiguous
axial slices) and a sagittal high resolution 3-dimensional T1w
sequence (MPRAGE, TR 2,110ms, TE 4.38ms, TI 1,100ms, flip
angle 15 degree, isotropic resolution 1 mm3). Conventional axial
spin-echo T1w (TR 1,060ms, TE 14ms, 3mm slice thickness, 44
contiguous axial slices) and axial T1w magnetization-prepared
images (MTI, TR 1,290ms, TE 14ms, 3mm slice thickness, 44
contiguous axial slices) were obtained before and 5min after
injection of 0.1 mmol/kg Gd-DTPA (Magnevist, Bayer-Schering,
Berlin, Germany). An axial epi-planar (EPI) diffusion-weighted
sequence (DWI, TR 9,400ms, TE 118ms, 3mm slice thickness,
matrix 1286128, b values 1 and 1,000 s/mm2) was acquired in
3 directions for the calculation of the ADC. Image quality was
reviewed according to pre-determined criteria. Raw data were
transferred to a Linux workstation and processed following a
semi-automated procedure described previously (21), including
an image coregistration (FMRIB’s Linear Image Registration
Tool, FMRIB Analysis Group, University of Oxford, Oxford,
UK) and inhomogeneity correction routine embedded into the
MedX v.3.4.3 software package (Sensor Systems Inc., Sterling,
VA, USA). Bulk white matter lesion load and lesion count of T2w
scans, as well as number and volume of contrast enhancing and
hypointense lesions on T1w scans, were routinelymeasured using
theMedX v.3.4.3 software package. Magnetization Transfer Ratio
(MTR) was calculated in MIPAV (Medical Image Processing,
Analysis, and Visualization, CIT-NIH, Bethesda, MD, USA) as
previously described (22). MRI analyses were conducted in an
anonymized way, applying a semi-automated procedure.
Statistical Analysis
Due to lack of data no statistical sample size calculation was
performed in advance using a given error of the 1st kind
and stipulated power. The chosen sample size of 80 patients
(40 in each arm) was based mainly on practicability. Due to
the explorative character of the study, statistical testing has to
be understood as explorative, and data analyses were mainly
descriptive for all endpoints. For univariate independent group
comparisons exact Mann-Whitney-U tests and exact Chi-Square
tests were used. For time series data, a nonparametric analysis
of longitudinal data in a two-factorial design was applied (1st
factor (independent): groups, 2nd factor (dependent): time).
Statistical significance was assumed at the p= 0.05 level. Because
of the explorative nature of analyses, no adjustments for multiple
comparisons were performed. Both, intent-to-treat (ITT) and
per-protocol (PP) analyses were carried out. The ITT group
comprised 30 patients (15 verum; 15 placebo). The PP definition
was regular study termination and mean study drug intake over
the complete study duration of at least 85% of the per protocol
scheduled intake. The PP group comprised 20 patients (11 verum;
9 placebo). All calculations were performed using SAS Version
9.4 [TS1M3] Copyright© 2002–2012 by SAS Institute Inc., Cary,
NC, USA, SPSS 24 (SPSS Inc., Chicago, IL, USA) and The R
Project for Statistical Computing, Version 3.4.0 (2017-04-21),
Copyright© 2017.
RESULTS
Of 35MS patients screened for participation in the FLORIMS
study, 30 patients were randomized and are included in the
ITT analyses. Of these, six patients prematurely terminated
study participation. The reasons for screening failure and
premature termination are provided in the CONSORT flow
diagram (Figure 2). The demographic characteristics of patients
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are presented in Table 1. There were no significant differences
between the verum and placebo groups.
Figure 2 shows the numbers of screened, randomized, and
analyzed patients in the respective groups. The reasons for
exclusion from randomization, drop out or exclusion from
analysis are displayed.
Clinical and MRI Endpoints
Important explorative clinical and MRI outcome parameters
(univariate, ITT population) are presented in Table 2. In the
verum group, nominal fewer patients had relapses, and the
number of contrast enhancing lesions was lower. However,
these differences were not significant. In summary, upon
12 months of continuous treatment with flupirtine, there
were no significant differences in the occurrence of relapses,
disability progression (EDSS, MSFC total, PASAT, TWT, 9HPT
individually), occurrence of contrast enhancing lesions, increase
in T2w lesion count and T2w lesion volume in comparison to
placebo treatment. Additional longitudinal multivariate analyses
of clinical parameters (EDSS, MSFC) also did not reveal a
FIGURE 2 | CONSORT flow diagram. ITT, intent to treat; PP, per protocol; n,
number.
significant treatment effect of flupirtine (not shown). Results were
comparable with those from the analysis of the PP population.
Safety Endpoints
The study drug was overall well tolerated. No safety concerns
were raised during the study. The number of documented adverse
events (AE) was higher in the verum group (n = 90) than in the
placebo group (n = 55), but this difference was not significant
(exact Chi-Square, p = 0.54). The majority of AE was mild or
moderate and not considered related to the study medication. Six
cases of asymptomatically elevated liver enzymes were recorded,
five in the verum group and one in the placebo group. Two of
these, both in the verum group, prematurely terminated study
participation. Two events in the verum group and one event
TABLE 1 | Patients characteristics and baseline data.
Verum Placebo
Total (n) [within group (%)] 15 [50] 15 [50] n.s.a
Female [within group (%)] 8 [57] 6 [47] n.s.a
Stratum lesion load high (n) [within
group (%)]
10 [67] 12 [80] n.s.a
Age (mean) 40 [2.0] 38 [2.8] n.s.b
Mean MS-duration since onset
(months) [SE]
115 [23] 122 [24] n.s.b
Mean treatment IFN β1b
(months) [SE]
60 [14] 52 [11] n.s.b
BMI [SE] 26,8 [1,1] 28 [2,4] n.s.b
EDSS (median) [range] 2.5 [1.5-4.0] 2.0 [0-4.0] n.s.b
Patients with CEL [within group (%)] 0 [0] 3 [20] n.s.a
Mean T2w lesion count (n) [SE] 29.4 [5.8] 27.6 [4.1] n.s.b
Mean T2w lesion volume (mm3) [SE] 4298 [978] 4399 [1209] n.s.b
This table displays themost relevant characteristics of study participants at randomization.
There were no significant differences between verum and placebo groups. BMI, body
mass index; EDSS, expanded disability status scale; CEL, contrast enhancing lesions; n,
number; n.s, not significant; SE, standard error.
aExact Chi-Square tests.
bExact Mann Whitney U-tests.
TABLE 2 | Main clinical and MRI outcome parameters after 12 months.
Verum Placebo
Patients with relapses (n) 2 6 n.s.a
Mean EDSS change [SE] −0.25 [0.14] + 0.38 [0.25] n.s.b
Mean PASAT change [SE] +3.2 [2.0] +10.7 [3.2] n.s.b
Mean TWT z-score change [SE] +0.8 [0.1] +0.2 [0.16] n.s.b
Mean 9HPT z-score change [SE] +0.5 [0.2] +0.1 [0.16] n.s.b
Total patients with CEL (n) 1 5 n.s.a
Total number of new T2w lesions (n) +6 +7 n.s.b
Mean T2w volume change (mm3) +306 +828 n.s.b
This table displays the most relevant outcome parameters after 12 months of double blind
treatment. There were no significant differences between verum and placebo groups.
EDSS, expanded disability status scale; CEL, contrast enhancing lesions; n, number;
n.s, not significant; PASAT, paced auditory serial addition test; TWT, timed walk test; SE,
standard error; 9HPT, 9-hole peg test.
aExact Chi-Square tests.
bExact Mann Whitney U-tests.
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in the placebo group were classified as severe (S) AE (bone
fracture, pulmonary embolism, cholecystectomy). None of these
was considered related to the study medication.
DISCUSSION
The FLORIMS study is the only trial so far that evaluated
the efficacy of flupirtine on MS disease activity when given in
addition to the standard disease modifying treatment IFN β1b.
The rationale for this trial was provided by flupirtine’s ability to
cross the blood brain barrier (9, 10) and the demonstration of
neuroprotective effects in both animals and humans (11–17). The
study was carefully planned, and several efforts have been done to
account for heterogeneity of patients and variability of data, e.g.,
stratification before randomization, monocentric MRI procedure
for all patients, training for EDSS raters, strict separation of
treating, and evaluating site personnel. We failed, however, to
detect any significant effect of 12 months treatment on multiple
exploratory clinical and MRI endpoints of disease activity.
Besides a true lack of efficacy, several methodological issues
need to be considered when interpreting these negative results.
First to mention is the small sample size. Due to unforeseen
substantial difficulties in the recruitment of initially targeted
80 participants, we had to prematurely terminate enrolment
after randomization of 30 patients, of which only 24 completed
the study on plan. Based on these numbers and a significance
threshold of α = 0.05, the power to detect significant changes
in EDSS was 59%. Twenty five patients per group would have
allowed a power of 80%, suggesting that the initially planned
40 patients per group would have probably been sufficient. In
light of the nominally lower numbers of both relapses and
patients with contrast enhancing lesions as well as the milder
increase of mean T2 hyperintense lesion volume in the verum
group we cannot exclude that the lack of significance in these
parameters is rather a consequence of poor power, i. e., that
the negative outcome might reflect a type II error. Next, the
number of relapses and new T2w or contrast enhancing lesions
was rather low indicating a population with fairly low disease
activity. This was probably at least in part attributable to the
IFN β treatment, but a non add-on study design would have
not been acceptable from an ethical point of view. Finally, the
treatment and observation period of 12 months was probably
not sufficient to evaluate the neuroprotective potential of the
compound.
Importantly, despite asymptomatic elevation of liver enzymes
in several cases we did not observe any clinically relevant
hepatotoxicity within approximately 15 treatment years with
300mg flupirtine per day which however will certainly not
influence the EMA decision to withdraw flupirtine from the
market.
In conclusion, the results of the FLORIMS study do not
add further evidence for neuroprotective or disease modifying
effects of flupirtine in MS, although in view of methodological
limitations a false negative outcome, i.e., a type II error cannot
be ruled out. Further research on flupirtine will however be
hampered by its expected withdrawal from the market.
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